Garcia-Manero, Guillermo <br/><br/>
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.  [electronic resource] 

 -  Investigational new drugs  Aug 2015 
 - 870-80 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-015-0242-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aminopyridines--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Aurora Kinases--antagonists & inhibitors<br/>Azacitidine--adverse effects<br/>Female<br/>Hematologic Neoplasms--drug therapy<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Phenylurea Compounds--adverse effects<br/>Protein Kinase Inhibitors--adverse effects<br/>Receptors, Vascular Endothelial Growth Factor